Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9357
Title: Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Authors: Kubota, E;Dean, Rachael G;Hubner, R A;Balding, Leanne C;Johnston, Colin I;Burrell, Louise M
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Studley Road, Heidelberg 3084, Victoria, Australia
Issue Date: 1-Dec-2001
Citation: Current Hypertension Reports; 3 Suppl 2(): S31-3
Abstract: In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme is responsible for the conversion of angiotensin I to angiotensin II, while neutral endopeptidase is one of the pathways involved in the degradation of the natriuretic peptides. The vasopeptidase inhibitors, which simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme, appear to offer distinct therapeutic advantages in treating hypertension, heart failure, and endothelial dysfunction.
Internal ID Number: 11716804
URI: http://ahro.austin.org.au/austinjspui/handle/1/9357
URL: http://www.ncbi.nlm.nih.gov/pubmed/11716804
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.pharmacology
Cardiotonic Agents.pharmacology
Endothelium, Vascular.drug effects
Heart.drug effects
Heart Failure.drug therapy
Humans
Hypertension.drug therapy
Kidney.drug effects
Kidney Failure, Chronic.drug therapy.etiology
Neprilysin.antagonists & inhibitors
Renin-Angiotensin System.drug effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.